Rare immuno-mediated adverse events: literature review


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Immune checkpoint inhibitors have heralded the advent of a “new era" in cancer treatment, significantly improving long-term survival of patients. While these novel agents are often well tolerated, they are widely known to cause a unique profile of immune-mediated toxicities. Any organ systems can be harmed be immune therapy, but the skin, gastro-intestinal tract, liver, lungs and endocrine system are most commonly affected. In recent years, an increasing number of atypical and sometimes life-threatening side effects have been reported, which requires early recognition and prompt intervention. This article reviews rare immune-related adverse events, their diagnosis and management.

Full Text

Restricted Access

About the authors

E. A Degtiareva

N.N. Petrov National Medical Research Center of Oncology

Email: degtyarevaekaterina@mail.ru
Oncologist, Postgraduate student at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. N Imyanitov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

References

  1. Schoenfeld S.R., Aronow M.E., Leaf R.K., et al. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020;25(1):6-14. doi: 10.1634/theoncologist.2019-0083.
  2. Kim J.M., Materin M.A., Sznol M., et al. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology. 2019;126(7):1058-62. doi: 10.1016/j.ophtha.2019.01.031.
  3. Fang T, Maberley D.A., and Etminanb M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319-22. doi: 10.1016/j.joco.2019.05.002.
  4. Michel L, Rassaf T., Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart & Vasculature. 2019;25:100420. Doi: 10.1016/j. ijcha.2019.100420.
  5. Agrawal N, Khunger A., Vachhani P, et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Rep Oncol. 2019;12:260-76. doi: 10.1159/000498985.
  6. Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55. Doi: 10.1056/ NEJMoa1609214.
  7. Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64. Doi: 10.1016/j. jacc.2018.02.037.
  8. Moslehi J.J., Salem J.E., Sosman J.A., et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2019; 391 (10124):933. doi: 10.1016/s0140-6736(18)30533-6.
  9. Upadhrasta S., Elias H., Patel K., et al. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6-14. doi: 10.1016/j.cdtm.2019.02.004.
  10. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Management of Immunotherapy-Related Toxicities, Version 1.2020 - December 16, 2019. Accessed at https://www.nccn.org/ professionals/physician_gls/pdf/immunotherapy. pdf on Februrary 25, 2020.
  11. Curigliano G., Lenihan D., Fradley M., et al. Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations. Ann Oncol. 2020;31(2):171-90. Doi: 10.1016/j. annonc.2019.10.023.
  12. Saade A., Mansuet-Lupo A., Arrondeau J., et al. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7:266. doi: 10.1186/s40425-019-0760-4.
  13. Khan A., Zhang H., Chen C., et al. Impact of pericardial effusion for patients receiving immune checkpoint inhibitors. J Clin Oncol. 2019;37:e14121-e14121. Doi: 10.1200/ JCO.2019.37.15_suppl.e14121.
  14. Shaheen S., Mirshahidi H., Nagaraj G., et al. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol 2018;7:11. doi: 10.1186/s40164-018-0104-y.
  15. Chen D.Y, Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immunooncology. J Formos Med Assoc. 2019;pii:S0929-6646(19)30408-5. doi: 10.1016/j.jfma.2019.07.025.
  16. Ederhy S., Cautela J., Ancedy Y, et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(18):1187-90. Doi: 10.1016/j. jcmg.2017.11.036.
  17. Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1.
  18. Cautela J., Rouby F., Salem J.E., et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol 2020;36(4):476-81. Doi: 10.1016/j. cjca.2019.11.035
  19. Al-Kindi S.G., Oliveira G.H. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for oncocardiology. Mayo Clin Proc 2016;91(1):81-3. doi: 10.1016/j.mayocp.2015.09.009
  20. Gelsomino F., Fiorentino M., Zompatori M., et al. Programmeddeath-1inhibitionandatherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 2018;29(1):284-86. doi: 10.1093/annonc/mdx718
  21. Daxini A., Cronin K. and Sreih A.G. Vasculitis associated with immune checkpoint inhibitors - a systematic review. Clin Rheumatol. 2018;37:2579-84. doi: 10.1007/s10067-018- 4177-0
  22. Jamal S., Hudson M., Fifi-Mah A., et al. Immunerelated Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020;47:166-75. doi: 10.3899/jrheum.190084
  23. Reynolds K.L., Guidon A.C. Diagnosis and Management of Immune Checkpoint InhibitorAssociated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019;24(4):435-43. Doi: 10.1634/ theoncologist.2018-0359
  24. Connolly C., Bambhania K. and Naidoo J. Immune Related Adverse Events: A Case-Based Approach. Front Oncol. 2019;9:530. Doi: 10.3389/ fonc.2019.00530
  25. Möhn N., Beutel G., Gutzmer R., et al. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J Clin Med. 2019;8(11):1777. doi: 10.3390/jcm8111777
  26. Cuzzubbo S., Javeri F., Tissier M., et al. Neurological adverse events associated with immune checkpoint 20 inhibitors: Review of the literature. Eur J Cancer. 2017;73:1-8. doi: 10.1016/j.ejca.2016.12.001
  27. Johnson D.B., Manouchehri A., Haugh A.M., et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2020;7(1):134. doi: 10.1186/s40425-019-0617-x
  28. Safa H., Johnson D.H., Trinh V.A., et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. doi: 10.1186/s40425-019- 0774-y
  29. Gravbrot N., Scherer K. and Sundararajan S. Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature. Case Rep Oncol Med. 2019;2019:5490707. doi: 10.1155/2019/5490707
  30. Gaudy-Marqueste C., Monestier S., Franques J., et al. A severe case of ipilimumab-induced GuillainBarre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumabinduced colitis. J Immunother. 2013;36(1):77-8. doi: 10.1097/CJI.0b013e31827807dd
  31. Bhatia S.,Huber B.R.,Upton M.P.,etal.Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32(2):203-5. doi: 10.1097/CJI.0b013e318193a206
  32. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-68. Doi: 10.1200/ JCO.2017.77.6385
  33. Haanen J., Carbonnel F., Robert C., et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-42. doi: 10.1093/annonc/ mdx225

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies